{"id":"W4387135688","doi":"10.1136/ijgc-2023-esgo.1","title":"#67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Carboplatin; Bevacizumab; Internal medicine; Oncology; Cervical cancer; Hazard ratio; Cancer; Gemcitabine; Progression-free survival; Chemotherapy; Cisplatin; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001766108,0.000920154,0.001682336,0.0005819701,0.0002560333,0.0009812117,0.0004871787,0.0007234411,0.005737412],"category_scores_gemma":[0.002060574,0.0004518332,0.008473866,0.0005830979,0.0002758984,0.0007431814,0.0005497456,0.00135724,0.000492425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008134329,"about_ca_system_score_gemma":0.001056663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002483432,"about_ca_topic_score_gemma":0.01022872,"domain_scores_codex":[0.9987904,0.0005303733,0.0001502935,0.00020915,0.0001203235,0.0001994112],"domain_scores_gemma":[0.9995359,0.00016321,0.0001287105,0.00006405728,0.00004253747,0.00006559592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7929037,0.001004265,0.04244533,0.005393513,0.06710543,0.0001824218,0.000119521,0.002024893,0.007824033,0.0005686985,0.01161009,0.06881819],"study_design_scores_gemma":[0.4643794,0.07068943,0.2633733,0.001557094,0.1503432,0.0005285426,0.000367598,0.007684634,0.004133414,0.003621955,0.03310386,0.0002174702],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9449142,0.02593045,0.003159057,0.001195194,0.001133621,0.003600667,0.01174877,0.000170158,0.008147906],"genre_scores_gemma":[0.9842755,0.002864272,0.001612788,0.001040778,0.0003417025,0.001934394,0.004451588,0.0000397053,0.003439345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005737412,"threshold_uncertainty_score":0.01919359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08366524295195818,"score_gpt":0.3744814509143597,"score_spread":0.2908162079624015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}